Genetic Heterogeneity in ADHD:
DAT1 Gene Only Affects Probands Without CD

Kaixin Zhou,[1] Wai Chen,[1] Jan Buitelaar,[2] Tobias Banaschewski,[3,4] Robert D. Oades,[5] Barbara Franke,[2,6] Edmund Sonuga-Barke,[7] Richard Ebstein,[8] Jacques Eisenberg,[9] Michael Gill,[10] Iris Manor,[8] Ana Miranda,[11] Fernando Mulas,[11] Herbert Roeyers,[12] Aribert Rothenberger,[3] Joseph Sergeant,[13] Hans-Christoph Steinhausen,[14] Jessica Lasky-Su,[15,16,17] Eric Taylor,[1] Keeley J. Brookes,[1] Xiaohui Xu,[1] Benjamin M. Neale,[1,18,19] Fruhling Rijsdijk,[1] Margaret Thompson,[7] Philip Asherson,[1] and Stephen V. Faraone[15,16,17]*

[1]MRC Social Genetic Developmental and Psychiatry Centre, Institute of Psychiatry, London, United Kingdom
[2]Department of Psychiatry, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
[3]Child and Adolescent Psychiatry, University of Göttingen, Germany
[4]Central Institute of Mental Health, Department of Child and Adolescent Psychiatry and Psychotherapy, Mannheim, Germany
[5]University Clinic for Child and Adolescent Psychiatry, Essen, Germany
[6]Department of Human Genetics, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands
[7]School of Psychology, University of Southampton, Highfield, Southampton, United Kingdom
[8]ADHD Clinic, Geha Mental Health Center, Petak Tikvah, Israel
[9]S. Herzog Memorial Hospital, Jerusalem, Israel
[10]Department of Psychiatry, Trinity Centre for Health Sciences, St. James's Hospital, Dublin, Ireland
[11]Department of Developmental and Educational Psychology, University of Valencia, Spain
[12]Ghent University, Ghent, Belgium
[13]Department of Clinical Neuropsychology, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
[14]Department of Child and Adolescent Psychiatry, University of Zurich, Switzerland
[15]Department of Psychiatry, SUNY Upstate Medical University, Syracuse, New York
[16]Department of Neuroscience, SUNY Upstate Medical University, Syracuse, New York
[17]Department of Physiology, SUNY Upstate Medical University, Syracuse, New York
[18]Broad Institute of Harvard and MIT, Cambridge, Massachusetts
[19]Center for Human Genetic Research, Massachusetts General Hospital, Boston, Massachusetts

Previous studies have found heterogeneous association between DAT1-3′-UTR-VNTR and attention deficit hyperactivity disorder (ADHD). Various proportions of conduct disorder (CD) comorbidity in their ADHD samples may partially explain the observational discrepancies. Evidence for this comes from family and twin studies which found ADHD probands with CD (ADHD + CD) are genetically different from those without CD (ADHD − CD). Genotypes of 20 DAT1 markers were analyzed in 576 trios, consisting of 141 ADHD + CD and 435 ADHD − CD. In addition to the classical TDT test, a specific genetic heterogeneity test was performed to identify variants that have different transmission patterns in the two phenotypic subgroups. After multiple-test correction, rs40184 and rs2652511 were significant in TDT tests. Further heterogeneity test found the two SNPs had a significant transmission pattern difference between ADHD + CD and ADHD − CD children, indicating that DAT1 has a significantly greater genetic influence on ADHD without CD. Although the result needs further replications, it does highlight the importance of selecting genetically homogeneous samples for molecular genetic analyses of ADHD.
© 2007 Wiley-Liss, Inc.

KEY WORDS: comorbidity; stratification; association

INTRODUCTION

Family, twin, and adoption studies have consistently shown that attention deficit hyperactivity disorder (ADHD) is highly heritable (>75%) with population prevalence estimated at 4–8% [Asherson, 2004; Heiser et al., 2004; Faraone et al., 2005;

Thapar et al., 2005; Waldman and Gizer, 2006]. However, there remains considerable uncertainty about the more specific etiology of ADHD. The rationale for early efforts to identify ADHD susceptibility genes using candidate gene approaches were largely guided by the fact that ADHD children responded favorably to stimulants such as methylphenidate and dexamphetamine [Spencer et al., 1996]. Based on the fact that these medications inhibit the dopamine transporter, the dopamine transporter gene (*DAT1* or *SLC6A3*) became a target of investigation [Cook et al., 1995]. During the last decade, mixed positive and negative findings emerged from a large number of independent studies exploring the association between *DAT1* and ADHD. The most intensively tested marker, a 40-bp variable number of tandem repeat (VNTR) located in the 3′-untranslated region (3′-UTR) was shown to have a small (OR = 1.13, 95% CI (1.03–1.31)) but significant effect in a meta-analysis that pooled family based studies together [Faraone et al., 2005]. More recently, however, a further meta-analysis of *DAT1* that included a more comprehensive analysis of available studies, found no overall evidence for association but significant evidence of heterogeneity between datasets [Li et al., 2006]. The reason for the observed heterogeneity is currently unknown.

One possible explanation for such heterogeneity is that the 40-bp VNTR is not the functional variant causing susceptibility and may tag one or more causal variants to different degrees from sample to sample. Evidence for this comes from the analysis of an additional 30-bp VNTR in intron 8 that showed association of ADHD to a specific haplotype of the two VNTR markers in UK and Taiwanese samples, as well as the IMAGE project sample (pooled OR = 1.4, $P = 6 \times 10^{-7}$) [Asherson et al., 2007]. The low resolution obtained by using only one marker may partially explain the inconsistent findings. Another possible source of inter-study heterogeneity is of a phenotypic nature. Like other psychiatric disorders, ADHD shows substantial phenotypic heterogeneity associated with different DSM-IV subtypes [Faraone et al., 2000a], the co-existence of various comorbid traits [Thapar et al., 2006], as well as variability in the persistence of symptoms across the lifespan [Faraone and Tsuang, 2001; Faraone et al., 2006]. Some of this heterogeneity is likely to have its origin in genetic differences between individuals [Faraone et al., 2000c]. In the current article, we set out to test whether the pattern of inter-study variability in the ADHD–*DAT1* association might be explained, at least in part, by heterogeneity within ADHD samples in relation to comorbid conduct disorder (CD).

The comorbidity between ADHD and CD has been observed consistently for many years. Taylor noted that the co-morbidity between ADHD and CD raises a key nosological question: are these two disorders best seen as co-occurring yet separate entities, or does their consistent co-occurrence signal the presence of a separate category of one or other of the disorders [Taylor, 1994]? The former approach was taken by the DSM-IV [Amercian Society of Psychiatry, 1994], whereas the latter has been recognized with the separate category of hyperkinetic CD used by the ICD-10 [World Health Organization, 1988]. To address this issue from a genetic epidemiologic perspective, Faraone and colleagues showed in several independent samples that the pattern of familial co-aggregation of DSM-defined ADHD and CD was consistent with the ICD-10 formulation of hyperkinetic CD as a discrete familial subtype [Faraone et al., 1995, 1998, 2000b, 2000c]. Data from other groups also favored a familial distinction between ADHD with CD (ADHD + CD) and other ADHD children (ADHD – CD). Lahey [1988] reported higher rates of antisocial disorders, depression, and substance abuse among relatives of ADHD + CD probands compared to ADHD – CD probands. Mothers of ADHD + CD children have also been found to have higher rates of psychopathology than the mothers of ADHD – CD children

[Lahey et al., 1989]. Parents of ADHD + CD children have been found to have higher rates of retrospectively reported childhood hyperactivity, CD, and substance use than parents of ADHD – CD children [Frick et al., 1991]. Together these findings indicate an increased familial co-segregation of the ADHD + CD phenotype; although they do not exclude the possibility of shared environmental effects on the familial co-transmission of CD with ADHD. Twin studies confirmed the familial co-aggregation of ADHD and CD [Szatmari et al., 1993; Silberg et al., 1996] and found that the genes influencing conduct problems were all shared with those effecting ADHD symptoms [Thapar et al., 2001]. These studies also showed the existence of some genetic effects that were unique to ADHD, as well as shared environmental effects on the risk for conduct problems but not ADHD. In recent psychophysiological studies of event-related potentials and task performance, the ADHD + CD group was found to be psychophysiologically less deviant or impaired than either pure ADHD group or pure CD group indicating that ADHD + CD might represent a separate disorder distinct from ADHD – CD [Banaschewski et al., 2003; Albrecht et al., 2005].

Driven by these compelling data, we hypothesize that comorbidity with CD partially accounts for the inter-study variability in the ADHD–*DAT1* association. In the current study, we set out to test this hypothesis by reanalyzing data from a previous candidate gene analysis utilizing data from the IMAGE project which provided nominal association evidence at the *DAT1* locus [Brookes et al., 2006].

MATERIALS AND METHODS

Subjects and Genotyping

In this study, we used data from our previous analysis of 51 candidate genes in which the association with *DAT1* reached gene-wide significance and suggested the existence of two independent associations at the 3′- and 5′-ends of the gene [Brookes et al., 2006]. The original nuclear family sample was stratified into independent ADHD + CD and ADHD – CD trios. This allowed us to formally carry out a standard chi-square test of genetic heterogeneity based on the transmission patterns in both groups.

European Caucasian subjects were recruited from 12 specialist clinics in eight countries: Belgium, Germany, Holland, Ireland, Israel, Spain, Switzerland, and United Kingdom. Ethical approval for the study was obtained from National Institute of Health registered ethical review boards for each center. All ADHD probands and their siblings were aged 5 to 17 at the time of entry into the study and access was required to one or both biological parents for DNA collection. Entry criteria for probands were a clinical diagnosis of DSM-IV combined subtype ADHD and having one or more full siblings available for ascertainment of clinical information and DNA collection. Exclusion criteria applying to both probands and siblings included autism, epilepsy, IQ < 70, brain disorders, and any genetic or medical disorder associated with externalizing behaviors that might mimic ADHD. For the analyses completed here, we selected the subset of 576 proband–parent trios for whom we had complete genotype data for markers across the *DAT1* gene.

The research diagnosis of DSM-IV ADHD and CD was reached following completion of a parent interview with the parent account childhood symptoms (PACS) [Taylor et al., 1986]. This is a semi-structured, standardized, investigator-based interview developed as an instrument to provide an objective measure of child behavior. For the diagnosis of ADHD, a standardized algorithm was applied to PACS data to derive each of the 18 DSM-IV ADHD items, providing operational definitions for each behavioral symptom. These were

then combined with items that scored 2 or 3 from the teacher rated Conners' ADHD subscale, to generate the total number of items from the DSM-IV symptom checklist. The definition of situational pervasiveness required that some symptoms occurred within two or more different situations from the PACS interview, or the presence of one or more symptoms scoring 2 or more from the ADHD subscale of the teacher rated Conners. The diagnosis of DSM-IV CD was based on the PACS data alone. All the CD diagnosis was made without the existence of oppositional defiant disorder (ODD). Of the 576 probands included in this analysis, 435 were diagnosed without CD (ADHD − CD) and 141 with CD (ADHD + CD). As shown in Table I, there is no significant age or sex difference between the two phenotypic subgroups. Table II describes the demographic distribution of the 576 trios. The ADHD + CD proband incidence rates are between 9 and 45% across our study sites. Using Pearson's chi-squared test of equal incidence across centers, we found the incidence rates significantly different between IMAGE centers through 10,000 simulations ($P = 0.0002$), suggesting a high degree of inter-site phenotypic heterogeneity in terms of CD.

We selected 18 common SNPs (minor allele frequency > 0.05) that had been successfully genotyped at the DAT1 locus in the original study. Genotypes from two VNTR markers including the most intensively investigated 3′-UTR 40-bp VNTR and the intron 8 30-bp VNTR were also included in this analysis [Asherson et al., 2007].

Statistical Tests

The Transmission Disequilibrium Test (TDT) was used to test for single marker associations [Ewens and Spielman, 2005]. For haplotype-specific TDT, the haplotype counts were obtained by summing the EM-estimated fractional likelihoods of each individual as implemented in Haploview [Barrett et al., 2005]. In addition, we used ETDT to test the multi-allele haplotype transmission disequilibrium [Sham and Curtis, 1995]. All the association tests were performed in each phenotypic subgroup separately and then in the full sample.

To detect genetic heterogeneity between the two subgroups, we used a standard chi-square test. Under the null hypothesis of no genetic heterogeneity, a variant is expected to have the same effect in both clinical subgroups, so that an allele of the marker will be expected to have the same transmission to non-transmission ratio (T/NT) from heterozygotic parents in each phenotypic subgroup. Thus, we counted the observed numbers of a particular allele transmitted and non-transmitted from heterozygotic parents to affected children in each subgroup as shown in the following 2×2 contingency table.

	ADHD + CD	ADHD − CD
Transmitted	a	b
Non-transmitted	c	d

Our test statistic was defined as:

$$\chi^2 = \sum_{ij} \frac{(O_{ij} - E_{ij})^2}{E_{ij}} = \frac{(ad - bc)^2(a + b + c + d)}{(a + b)(c + d)(b + d)(a + c)}$$

where O_{ij} denotes the observed counts of the alleles in each cell and E_{ij} denotes the expected counts of the alleles in each cell under the null hypothesis. The i denotes two subgroups (1 = ADHD + CD, 2 = ADHD − CD) and j denotes whether the allele is transmitted (1 = transmitted, 2 = non-transmitted). The a, b, c, and d are the observed cell counts. Significance level

was evaluated against χ^2 distribution with 1 degree of freedom. A significant test statistic would support the alternative hypothesis that transmission patterns of this allele are significantly different between the two subgroups. In other words, the marker has significantly different genetic effect on the two subgroups. When the test is used for SNPs, the statistic is the same for two alleles because their transmissions are mutually exclusive. For the two VNTRs, we reported the test statistics for the previously identified 10R (for the VNTR in the 3′-UTR) and 3R (for the VNTR in intron 8) alleles [Asherson et al., 2007].

RESULTS
Single Marker Association Analysis

The 18 SNP and two VNTR markers analyzed here covered the whole DAT1 genomic region with an average density of 1 marker/2.85 kb. Figure 1 shows the pairwise linkage disequilibrium (LD) measure D′ in the founders as estimated by GOLD [Abecasis and Cookson, 2000]. The three-block structure pattern is consistent with that identified in a recent comprehensive study of the DAT1 genomic region [Greenwood et al., 2006]. Both VNTR markers fall into the 3′-end block with the 40-bp VNTR in tight LD with other SNPs and the 30-bp VNTR at the boundary of this block. This pattern suggests that the previous association studies using these two VNTRs can only pick up association signals from the 3′-end of the DAT1 locus.

Table III summarizes the single marker TDT test results in each phenotypic subgroup and the full sample. The two VNTRs only showed marginal associations ($P < 0.1$) in both the ADHD − CD group and the full sample. Five SNPs (rs40184, rs2652511, rs11564750, rs10070282, rs2550946) showed nominally significant ($P < 0.05$) associations in both the ADHD − CD group and the full sample. In particular, rs40184 ($P = 0.0004$) from the 3′-end LD block in DAT1 and rs2652511 ($P = 0.002$) from the 5′-end LD block were still significant in the ADHD − CD group after the stringent Bonferroni multiple test correction ($P < 0.0025$). More importantly, because these two SNPs locate in separate LD blocks with D′ = 0.15 between them (95% CI: 0.09–0.2), we can view them as independent association signals at the DAT1 locus. Strikingly, none of the markers showed any association signal within the ADHD + CD group.

Single Marker Genetic Heterogeneity Test

The genetic heterogeneity tests between ADHD + CD and ADHD − CD are also summarized in Table III. The two significant SNPs (rs40184, rs2652511) from the association test in the ADHD − CD group also showed significant genetic heterogeneity between groups ($P = 0.016$ and $P = 0.023$). In addition, rs27072 showed significant heterogeneity ($P = 0.034$), but has only a marginal association with the ADHD − CD group ($P = 0.06$) and no association with the ADHD + CD group ($P = 0.168$). Owing to the multiple LD block structures at the DAT1 locus and the heterogeneity signals seen in the two blocks, we opted to perform simulations to estimate the statistical significance of observing two such independent signals. In each simulation, only the proband diagnosis was permuted to preserve the LD structure. The heterogeneity test was performed on each permuted data set and the highest statistic from each LD block was collected. From 10,000 simulations, 181 were observed with multiple significant heterogeneity signals ($P < 0.05$) from different LD blocks, simultaneously. Thus the empirical significance of our finding is $P = 0.018$.

TABLE I. Age and Sex Distribution in the Two Subgroups

	ADHD + CD	ADHD − CD	P-value[a]
Age	10.86 ± 2.88	10.91 ± 2.70	0.87
Sex (male:female)	128:13	374:61	0.12
# DSM-IV symptoms	16.38 ± 1.38	16.75 ± 1.25	0.003

[a]Both tests were performed with functions in R statistical package. Significance for age and number of DSM-IV ADHD symptom difference was from the standard t-test function t.test. Significance for sex difference was from the equal proportion test function prop.test.

Haplotype Analysis

Table IV presents haplotype-specific TDT tests of the two significant SNPs (rs40184, rs2652511) in both subgroups, and the heterogeneity test. As expected, all four haplotype-specific TDT tests were non-significant in the ADHD + CD subgroup ($P > 0.1$). On the contrary, the most common GG haplotype (35.3%) is significantly over-transmitted in the ADHD − CD group (haplotype specific $P = 1.6 \times 10^{-6}$). The AA haplotype showed a moderate protective effect. In a 3-df likelihood test of transmission disequilibrium, the two locus haplotype transmission is significantly distorted in the ADHD − CD group ($P = 8.5 \times 10^{-5}$). Finally, the transmission patterns of the GG haplotype were significantly different ($P = 0.0009$) in the chi-square test of genetic heterogeneity between the two subgroups. This was due to significant over-transmission in the ADHD − CD subgroup and non-significant under-transmission in the ADHD + CD subgroup.

DISCUSSION

In this study, TDT tests in ADHD + CD and ADHD − CD subgroups gave very different results. Two SNPs (rs40184 and rs2652511) from the $DAT1$ gene were significantly associated with ADHD − CD after the application of the stringent Bonferroni correction for multiple tests. In the haplotype-specific TDT test at these two loci, a highly significant ($P = 1.6 \times 10^{-6}$) association was observed between the GG haplotype and the ADHD − CD phenotype. In contrast, none of the 20 markers were associated with ADHD + CD even without correction. When the two phenotypic subgroups were combined, there were only nominally significant signals, but none of them remained after multiple test correction. One potential explanation for this observational contrast is age or gender difference between the subgroups. However, as shown in Table I, neither age nor sex is significantly different between the two subgroups. Another possible explanation might be the

genetic mechanisms associated with varying levels of comorbid CD across samples. We applied a formal statistical test to address whether observing the different association results in ADHD + CD and ADHD − CD was due to genetic heterogeneity or simply occurred by chance. The test statistic was calculated with heterozygous parents' allele T/NT to ensure it was robust for population stratification. Our single marker genetic heterogeneity tests identified significant SNPs in two LD blocks at the $DAT1$ locus. Further permutation results suggested the chance of observing such a pattern of genetic heterogeneity under the LD background as being very low ($P = 0.018$). Thus, we are confident that the significance of the subgroup difference in the transmission pattern really indexes the impact of phenotypic heterogeneity. Considering the fact that a significant association was only found within the ADHD − CD subgroup, our data may further indicate that variation in $DAT1$ is only implicated in the genetic etiology of ADHD children who do not have CD.

Rather than an allele frequency-based pseudo case-control test, we preferred to use a T/NT ratio-based test statistic in our heterogeneity test in this study because potential population stratification is a potential concern in the IMAGE multi-country sample [Neale et al., 2007]. Population stratification may lead to different allele frequencies in subgroups and produce either false positive or false negative results in case-control studies. For example, in the haplotype analysis shown in Table IV, our T/NT ratio-based test demonstrated significant ($P = 0.0009$) heterogeneity in the transmission of GG haplotype. However, using a pseudo case-control mannered test to compare allele frequency between the two subgroups would have found no significant difference and produced a false negative result. Thus, our data provided an example of taking advantage of a family based study design to avoid the potential bias associated with population stratification.

The findings in this report may also shed some light on the debate over whether ADHD + CD is quantitatively or qualitatively different from ADHD − CD in its genetic etiology. The

TABLE II. Sample Demographic Distribution

Study site	# ADHD − CD	# ADHD + CD	Full sample	ADHD + CD incidence rate (%)
Site 1	45	20	65	31
Site 2	20	5	25	20
Site 3	63	13	76	17
Site 4	13	8	21	38
Site 5	16	5	21	24
Site 6[a]	41	33	74	45
Site 7	20	2	22	9
Site 8	51	23	74	31
Site 9	35	13	48	27
Site 10	87	14	101	14
Site 11	44	5	49	10
Total	435	141	576	24

[a]Two study sites from UK were merged because one of them has only a few families.

Fig. 1. Linkage disequilibrium pattern and block structure at *DAT1* locus. The diagram was plotted on the D' scale estimated from the founders. The two circled SNPs, *rs40184* and *rs2652511* were used in our haplotype analysis. LD between them is D'=0.159 with 95% CI (0.1–0.21).

quantitative theory has its origins in twin model fitting results that suggest a liability threshold model in which genetic factors associated with CD are entirely shared by ADHD and ADHD + CD is a genetically more severe form of ADHD [Thapar et al., 2001]. According to this view, the same set of causal genes determines both phenotypes but has stronger effects on the ADHD + CD subgroup. On the other hand, key evidence supporting the qualitative theory comes from familial studies showing that relatives of ADHD − CD children have a similar risk for CD as relatives of normal controls [Faraone et al., 1998, 2000c]. From this perspective, it is reasonable to infer at the molecular level, that ADHD + CD genes do not have to confer risk for ADHD − CD or vice versa. In the current study, we tested gene effects in both subgroups and found *DAT1* conferring a significant risk for ADHD − CD but a non-significant protective effect for ADHD + CD. This result does not support the liability threshold model, which predicts a gene having unidirectional effects on both groups, but is fully compatible with the prediction of the qualitative theory, which suggests *DAT1* as a potential ADHD − CD-specific gene.

A few studies have reported post hoc association tests with dopamine genes in ADHD + CD children after having non-significant results with the full ADHD sample. Two earlier studies did find DRD4 was only associated in ADHD children with conduct problems [Holmes et al., 2002; Kirley et al., 2003]. Another recent cohort study found no association between DRD4 and ADHD + CD [Mill et al., 2006]. However, none of them reported association tests in the ADHD − CD subgroup because they all had an a priori hypothesis that genes conferring risk for ADHD − CD would also affect ADHD + CD with bigger effect size. Moreover, there was no statistical evidence in these studies indicating DRD4 to have more influence on ADHD + CD because the ADHD − CD subgroup has been ignored in their secondary analysis. Therefore, it is questionable that the significant observations in the ADHD + CD groups of the aforementioned studies were simply due to random allelic fluctuations when the original sample

TABLE III. Single Marker TDT Test and Heterogeneity Test for 18 Common SNPs and Two VNTRs at the *DAT1* Locus

| Marker | Allele 1 | Allele 2 | Position | MAF | TDT test P-values | | | Likelihood ratio test of heterogeneity | | | | |
| | | | | | ADHD − CD | ADHD + CD | Full sample | ADHD − CD | | ADHD + CD | | |
								T	NT	T	NT	χ^2-P
rs7732456	A	C	1445965	0.0656	0.2167	0.1137	0.0722	62	49	17	9	0.3722
40bp-VNTR	10R	9R	1447327	—	0.0602	0.6985	0.0664	191	156	54	50	0.5756
rs27072	A	G	1447522	0.1577	0.0604	0.1678	0.3380	105	134	44	32	**0.0337**
rs1042098	A	G	1447815	0.2809	0.0997	0.4369	0.0691	193	162	57	49	0.9146
rs40184[a]	A	G	1448077	0.4420	**0.0004**	0.5376	**0.0054**	173	245	68	61	**0.0239**
rs6869645	A	G	1457548	0.0627	0.7738	0.8474	0.7316	53	56	13	14	0.9643
30bp-VNTR	3R	2R	1464634	—	0.0693	1.0000	0.0997	161	130	32	32	0.5982
rs11564758	C	G	1473588	0.3960	0.1494	0.5838	0.3154	188	217	63	57	0.2417
rs464049	A	G	1476905	0.4351	0.5962	0.8586	0.7029	221	210	62	64	0.6827
rs463379	C	G	1484164	0.2222	0.7282	0.3120	0.8407	152	146	44	54	0.2937
rs460000	A	C	1485825	0.2220	0.7725	0.3169	0.8023	152	147	45	55	0.3119
rs403636	A	C	1491354	0.1688	0.2451	0.6275	0.4250	111	129	36	32	0.3297
rs13189021	A	G	1495842	0.2305	0.2717	0.2201	0.7247	159	140	42	54	0.1077
rs6350	A	G	1496199	0.0657	0.9215	0.8618	1.0000	52	51	16	17	0.8415
rs2652511[a]	A	G	1499389	0.4100	**0.0020**	0.2847	**0.0276**	184	248	69	57	**0.0160**
rs11564751	A	G	1500223	0.0714	0.5101	0.8658	0.5107	53	60	17	18	0.8629
rs11564750	C	G	1500762	0.0900	**0.0226**	0.2064	**0.0092**	57	84	21	30	0.9257
rs3756450	A	G	1501148	0.1211	0.2159	0.7855	0.2227	103	86	28	26	0.7311
rs10070282	A	G	1503444	0.4199	**0.0038**	0.5407	**0.0254**	246	186	62	69	0.0532
rs2550946	A	G	1503513	0.4201	**0.0027**	0.7237	**0.0140**	184	246	66	62	0.0804

The position of the variants is based on NCBI assembly 35. Minor Allele Frequency (MAF) is based on founder genotypes. ADHD + CD indicates the ADHD comorbid with CD group, ADHD − CD indicates the ADHD only group. Both TDT and heterogeneity tests were based on allele 1. Nominal significant P-values are marked in bold. The numbers of transmitted and non-transmitted allele 1 in each subgroup are also provided to differentiate the risk alleles in each subgroup. The markers can be divided into three LD blocks as separated by solid lines.
[a]SNPs rs2652511 and rs40184 were used in the haplotype analysis.

TABLE IV. TDT Test of *rs40184* and *rs2652511* haplotypes

| Haplotype | ADHD − CD (n = 435) | | | | ADHD + CD (n = 141) | | | |
	Allele frequency (%)	T	NT	P-value	Allele frequency (%)	T	NT	P-value
AA	22.7	138.8	189.5	0.005	20.6	54.1	39.4	$P > 0.1$
AG	23.0	148.2	173.5	$P > 0.1$	21.6	46.9	55.6	$P > 0.1$
GA	19.1	144.6	170.1	$P > 0.1$	18.7	52.9	45.9	$P > 0.1$
GG	35.3	275.4	173.9	1.6×10^{-6}	39.1	63.4	76.4	$P > 0.1$

The allele frequency was estimated by EM algorithm. The P-values in the table are haplotype-specific *1-df* TDT test. A *3-df* ETDT test resulted in $P = 8.5 \times 10^{-5}$ for the ADHD − CD group and $P = 0.8$ for the ADHD + CD group. A *1-df* chi-square test of heterogeneity on the GG haplotype resulted in $P = 0.0009$.

was subdivided. In the current study, both ADHD + CD and ADHD − CD subgroups were used in the heterogeneity test. It is the comparison between them that provided the statistical evidence indicating *DAT1* as a potential ADHD − CD-specific gene. This result suggests that the ADHD − CD subgroup is equally important to the ADHD + CD subgroup in terms of mapping genes underlying ADHD genetic heterogeneity and should not be precluded.

More generally, our findings highlight the importance of establishing genetically homogeneous samples for ADHD molecular genetic studies. In this study, we stratified our ADHD sample based on the prior knowledge that ADHD + CD may have a different genetic etiology compared to ADHD − CD. Our results do suggest that strong ADHD–*DAT1* associations can only be detected with the ADHD − CD subgroup sample. Similarly, other phenotypic features such as DSM-IV subtype and symptom persistence may also be determined by genetic difference to some extent [Faraone et al., 2000c; Thapar et al., 2006]. As shown by some association studies, *DAT1* and DRD5 have stronger effects on the development of inattentive subtype symptoms [Waldman et al., 1998; Lowe et al., 2004]. These results suggest that investigating specific phenotype subgroups may help to dissect the molecular genetic basis of ADHD. The main difficulty of using such stratified subgroup designs is the recruitment burden to get sufficient statistical power. For example, only about a quarter of the total ADHD sample in the current study also had CD. There will be little or no extra power to detect ADHD + CD associations with only a quarter of the total sample, unless the gene effect is specific to ADHD + CD or contributes a significantly higher risk to ADHD + CD. Nevertheless, with the rapid growth of large-scale international cooperation in ADHD molecular studies, we will be able to achieve sizable phenotypically homogeneous samples and test specific hypotheses with them.

In summary, the genetic heterogeneity test in this study found that variations in the *DAT1* gene confer significantly different risks to ADHD children with and without CD. Combined with the association findings in each subgroup, we found that *DAT1* was only associated with ADHD children without CD. This result may partially explain the observational inter-study heterogeneity in previous ADHD–*DAT1* associations. It also highlights the importance of using genetically homogeneous samples in ADHD molecular genetic studies. Given the presence of significant CD incidence rate difference among our recruiting sites and the large amount of statistical tests performed in the current investigation, we believe further replications are needed to confirm the above conclusions [Sullivan, 2007].

REFERENCES

Abecasis GR, Cookson WO. 2000. GOLD—Graphical overview of linkage disequilibrium. Bioinformatics 16(2):182–183.

Albrecht B, Banaschewski T, Brandeis D, Heinrich H, Rothenberger A. 2005. Response inhibition deficits in externalizing child psychiatric disorders: An ERP-study with the stop-task. Behav Brain Funct 1:22.

Amercian Society of Psychiatry. 1994. Diagnostic and Statistical Manual of Mental Disorders. 4th edition. Washington DC: American Psychiatric Association.

Asherson P. 2004. Attention-deficit hyperactivity disorder in the post-genomic era. Eur Child Adolesc Psychiatry 13 (Suppl 1):I50–I70.

Asherson P, Brookes K, Franke B, Chen W, Gill M, Ebstein RP, Buitelaar J, Banaschewski T, Sonuga-Barke E, Eisenberg J, Manor I, Miranda A, Oades RD, Roeyers H, Rothenberger A, Sergeant J, Steinhausen HC, Faraone SV. 2007. Confirmation that a specific haplotype of the dopamine transporter gene is associated with combined-type ADHD. Am J Psychiatry 164(4):674–677.

Banaschewski T, Brandeis D, Heinrich H, Albrecht B, Brunner E, Rothenberger A. 2003. Association of ADHD and conduct disorder—Brain electrical evidence for the existence of a distinct subtype. J Child Psychol Psychiatry 44(3):356–376.

Barrett JC, Fry B, Maller J, Daly MJ. 2005. Haploview: Analysis and visualization of LD and haplotype maps. Bioinformatics 21(2):263–265.

Brookes K, Xu X, Chen W, Zhou K, Neale B, Lowe N, Aneey R, Franke B, Gill M, Ebstein R, Buitelaar J, Sham P, Campbell D, Knight J, Andreou P, Altink M, Arnold R, Boer F, Buschgens C, Butler L, Christiansen H, Feldman L, Fleischman K, Fliers E, Howe-Forbes R, Goldfarb A, Heise A, Gabriels I, Korn-Lubetzki I, Marco R, Medad S, Minderaa R, Mulas F, Muller U, Mulligan A, Rabin K, Rommelse N, Sethna V, Sorohan J, Uebel H, Psychogiou L, Weeks A, Barrett R, Craig I, Banaschewski T, Sonuga-Barke E, Eisenberg J, Kuntsi J, Manor I, McGuffin P, Miranda A, Oades RD, Plomin R, Roeyers H, Rothenberger A, Sergeant J, Steinhausen HC, Taylor E, Thompson M, Faraone SV, Asherson P, Johansson L. 2006. The analysis of 51 genes in DSM-IV combined type attention deficit hyperactivity disorder: Association signals in DRD4, DAT1 and 16 other genes. Mol Psychiatry 11:934–953.

Cook EH Jr, Stein MA, Krasowski MD, Cox NJ, Olkon DM, Kieffer JE, Leventhal BL. 1995. Association of attention-deficit disorder and the dopamine transporter gene. Am J Hum Genet 56(4):993–998.

Ewens WJ, Spielman RS. 2005. What is the significance of a significant TDT? Hum Hered 60(4):206–210.

Faraone SV, Tsuang MT. 2001. Adult attention deficit hyperactivity disorder. Curr Psychiatry Rep 3(2):129–130.

Faraone SV, Biederman J, Chen WJ, Milberger S, Warburton R, Tsuang MT. 1995. Genetic heterogeneity in attention-deficit hyperactivity disorder (ADHD): Gender, psychiatric comorbidity, and maternal ADHD. J Abnorm Psychol 104(2):334–345.

Faraone SV, Biederman J, Mennin D, Russell R, Tsuang MT. 1998. Familial subtypes of attention deficit hyperactivity disorder: A 4-year follow-up study of children from antisocial-ADHD families. J Child Psychol Psychiatry 39(7):1045–1053.

Faraone SV, Biederman J, Friedman D. 2000a. Validity of DSM-IV subtypes of attention-deficit/hyperactivity disorder: A family study perspective. J Am Acad Child Adolesc Psychiatry 39(3):300–307.

Faraone SV, Biederman J, Monuteaux MC. 2000b. Attention-deficit disorder and conduct disorder in girls: Evidence for a familial subtype. Biol Psychiatry 48(1):21–29.

Faraone SV, Biederman J, Monuteaux MC. 2000c. Toward guidelines for pedigree selection in genetic studies of attention deficit hyperactivity disorder. Genet Epidemiol 18(1):1−16.

Faraone SV, Perlis RH, Doyle AE, Smoller JW, Goralnick JJ, Holmgren MA, Sklar P. 2005. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry 57(11):1313−1323.

Faraone SV, Biederman J, Mick E. 2006. The age-dependent decline of attention deficit hyperactivity disorder: A meta-analysis of follow-up studies. Psychol Med 36(2):159−165.

Frick PJ, LB B, CM G, Green S. 1991. History of childhood behavior problems in biological relatives of boys with attention deficit hyperactivity disorder and conduct disorder. J Clin Child Psychol 20(4):445−451.

Greenwood TA, Schork NJ, Eskin E, Kelsoe JR. 2006. Identification of additional variants within the human dopamine transporter gene provides further evidence for an association with bipolar disorder in two independent samples. Mol Psychiatry 11(2):125−133, 115.

Heiser P, Friedel S, Dempfle A, Konrad K, Smidt J, Grabarkiewicz J, Herpertz-Dahlmann B, Remschmidt H, Hebebrand J. 2004. Molecular genetic aspects of attention-deficit/hyperactivity disorder. Neurosci Biobehav Rev 28(6):625−641.

Holmes J, Payton A, Barrett J, Harrington R, McGuffin P, Owen M, Ollier W, Worthington J, Gill M, Kirley A, Hawi Z, Fitzgerald M, Asherson P, Curran S, Mill J, Gould A, Taylor E, Kent L, Craddock N, Thapar A. 2002. Association of DRD4 in children with ADHD and comorbid conduct problems. Am J Med Genet 114(2):150−153.

Kirley A, Lowe N, Hawi Z, Mullins C, Daly G, Waldman I, McCarron M, O'Donnell D, Fitzgerald M, Gill M. 2003. Association of the 480 bp DAT1 allele with methylphenidate response in a sample of Irish children with ADHD. Am J Med Genet B Neuropsychiatr Genet 121B(1):50−54.

Lahey BB, Piacentini JC, McBurnett K, Stone P, Hartdagen S, Hynd G. 1988. Psychopathology in the parents of children with conduct disorder and hyperactivity. J Am Acad Child Adolesc Psychiatry 27(2):163−170.

Lahey BB, Russo MF, Walker JL, Piacentini JC. 1989. Personality characteristics of the mothers of children with disruptive behavior disorders. J Consult Clin Psychol 57(4):512−515.

Li D, Sham PC, Owen MJ, He L. 2006. Meta-analysis shows significant association between dopamine system genes and attention deficit hyperactivity disorder (ADHD). Hum Mol Genet 15(14):2276−2284.

Lowe N, Kirley A, Hawi Z, Sham P, Wickham H, Kratochvil CJ, Smith SD, Lee SY, Levy F, Kent L, Middle F, Rohde LA, Roman T, Tahir E, Yazgan Y, Asherson P, Mill J, Thapar A, Payton A, Todd RD, Stephens T, Ebstein RP, Manor I, Barr CL, Wigg KG, Sinke RJ, Buitelaar JK, Smalley SL, Nelson SF, Biederman J, Faraone SV, Gill M. 2004. Joint analysis of the DRD5 marker concludes association with attention-deficit/hyperactivity disorder confined to the predominantly inattentive and combined subtypes. Am J Hum Genet 74(2):348−356.

Mill J, Caspi A, Williams BS, Craig I, Taylor A, Polo-Tomas M, Berridge CW, Poulton R, Moffitt TE. 2006. Prediction of heterogeneity in intelligence and adult prognosis by genetic polymorphisms in the dopamine system among children with attention-deficit/hyperactivity disorder: Evidence from 2 birth cohorts. Arch Gen Psychiatry 63(4):462−469.

Neale BM, Sham PC, Purcell S, Banaschewski T, Buitelaar J, Franke B, Sonuga-Barke E, Ebstein R, Eisenberg J, Mulligan A, Gill M, Miranda A, Manor I, Mulas F, Oades RD, Roeyers H, Rothenberger A, Sergeant J, Steinhausen HC, Taylor E, Thompson M, Zhou K, Asherson P, Faraone SV. 2007. Population differences in the International Multi-centre ADHD Gene (IMAGE) Project.

Sham PC, Curtis D. 1995. An extended transmission/disequilibrium test (TDT) for multi-allele marker loci. Ann Hum Genet 59(Pt 3):323−336.

Silberg J, Rutter M, Meyer J, Maes H, Hewitt J, Simonoff E, Pickles A, Loeber R, Eaves L. 1996. Genetic and environmental influences on the covariation between hyperactivity and conduct disturbance in juvenile twins. J Child Psychol Psychiatry 37(7):803−816.

Spencer T, Biederman J, Wilens T, Harding M, O'Donnell D, Griffin S. 1996. Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. J Am Acad Child Adolesc Psychiatry 35(4):409−432.

Sullivan PF. 2007. Spurious genetic associations. Biol Psychiatry 61(10):1121−1126.

Szatmari P, Boyle MH, Offord DR. 1993. Familial aggregation of emotional and behavioral problems of childhood in the general population. Am J Psychiatry 150(9):1398−1403.

Taylor E. 1994. Similarities and differences in DSM-IV and ICD-10 diagnostic criteria. Child Adolesc Psychiatr Clin N Am 3(2).

Taylor E, Everitt B, Thorley G, Schachar R, Rutter M, Wieselberg M. 1986. Conduct disorder and hyperactivity: II. A cluster analytic approach to the identification of a behavioural syndrome. Br J Psychiatry 149:768−777.

Thapar A, Harrington R, McGuffin P. 2001. Examining the comorbidity of ADHD-related behaviours and conduct problems using a twin study design. Br J Psychiatry 179:224−229.

Thapar A, O'Donovan M, Owen MJ. 2005. The genetics of attention deficit hyperactivity disorder. Hum Mol Genet 14(2):R275−R282.

Thapar A, Langley K, O'Donovan M, Owen M. 2006. Refining the attention deficit hyperactivity disorder phenotype for molecular genetic studies. Mol Psychiatry 11(8):714−720.

Waldman ID, Gizer IR. 2006. The genetics of attention deficit hyperactivity disorder. Clin Psychol Rev 26:396−432.

Waldman ID, Rowe DC, Abramowitz A, Kozel ST, Mohr JH, Sherman SL, Cleveland HH, Sanders ML, Gard JM, Stever C. 1998. Association and linkage of the dopamine transporter gene and attention-deficit hyperactivity disorder in children: Heterogeneity owing to diagnostic subtype and severity. Am J Hum Genet 63(6):1767−1776.

World Health Organization. 1988. ICD-10: Draft of Chapter V-Mental, Behavioural and Developmental Disorders. WHO, Division of Mental Health.